Homeopathy 2020; 109(01): A1-A28
DOI: 10.1055/s-0040-1702091
Oral Abstracts
The Faculty of Homeopathy

Effects of Individualized Homeopathic Intervention in Stage I Essential Hypertension: A Single-Blind Randomized, Placebo-Controlled Trial

Roja Varanasi
1  Central Council for Research in Homoeopathy (CCRH), New Delhi, India
,
Raju Kolli
2  Homoeopathy Research Institute for Disabilities, Chennai, India
,
Yogendra Rai
3  Dr DP Rastogi Central Research Institute (Homoeopathy), Noida, Uttar Pradesh, India
,
Ramesh Dubashi
4  Drug Standardization Unit, Hyderabad, Telangana, India
,
G. Ravi Chandra Reddy
5  Regional Research Institute (H), Gudivada, Andhra Pradesh, India
,
Tejaswini Patole
6  Regional Research Institute (H), Mumbai, Maharashtra, India
,
Priyanka Shrivastava
1  Central Council for Research in Homoeopathy (CCRH), New Delhi, India
,
Arvind Dayal
1  Central Council for Research in Homoeopathy (CCRH), New Delhi, India
,
Praveen Oberai
1  Central Council for Research in Homoeopathy (CCRH), New Delhi, India
,
Raj K. Manchanda
1  Central Council for Research in Homoeopathy (CCRH), New Delhi, India
› Author Affiliations
Further Information

Publication History

Publication Date:
05 February 2020 (online)

 

Background: Hypertension is the fourth-leading risk factor for death and disability and responsible for over 1.6 million deaths in India. Clinical case reports, observational studies and RCTs have shown homeopathy’s effectiveness in managing hypertension. The results of this study will add to the evidence of effectiveness of individualized homeopathic medicine in stage I hypertension.

Material and Methods: A randomised placebo-controlled single-blind pilot trial was undertaken at five research institutes, under the auspices of the CCRH, from October 2013 to March 2018. Out of 1946 patients screened, 217 patients suffering from Stage I hypertension and fitting the inclusion criteria were randomized to receive either Homeopathy + life-style modification (H+LSM) = 116 or Placebo + LSM = 101. Patients in the verum arm were administered individualized homeopathic medicine in Q potency. The primary outcome measure to evaluate the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were assessed every month for three months. Analysis was by intention to treat.

Results: Repeated measure ANOVA between the groups showed statistically significant differences (Wilk Lambda 0.85, F = 12.12, df = 213; p = 0.0001) in both SBP and DBP, favouring the H+LSM group. Post-hoc independent t-test showed a significant mean reduction of SBP [mean diff. 7.12; 95% CI, 4.72 to 9.53; p = 0.0001] and mean reduction in DBP [mean diff 5.76; 95% CI, 4.18 to 7.23; p = 0.0001] favouring the H+LSM group. Sulphur (n = 24), Natrum mur. (n = 21), Lycopodium (n = 16), Nux vom. (n = 12) and Phosphorus (n = 10) were the most frequently prescribed medicines.

Conclusion: Individualized homeopathy + LSM was found effective over placebo + LSM in patients suffering from Stage I hypertension. Further trials in a rigorous setting are warranted.

Keywords: Stage I hypertension, individualized homeopathy, Q potency